# Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs

> **NCT00062816** · PHASE1,PHASE2 · COMPLETED · sponsor: **Ionis Pharmaceuticals, Inc.** · enrollment: 22 (—)

## Conditions studied

- Hepatitis C, Chronic

## Interventions

- **DRUG:** ISIS 14803, peginterferon alfa, ribavirin

## Key facts

- **NCT ID:** NCT00062816
- **Lead sponsor:** Ionis Pharmaceuticals, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2003-06
- **Primary completion:** 2004-01
- **Final completion:** 2004-01
- **Target enrollment:** 22 (—)
- **Last updated:** 2022-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00062816

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00062816, "Addition of ISIS 14803 to Therapy With Peginterferon and Ribavirin for Chronic Hepatitis C (HCV) Patients Not Responding Adequately to the Two Drugs". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00062816. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*